Crespo, M
van Dalum, G
Ferraldeschi, R
Zafeiriou, Z
Sideris, S
Lorente, D
Bianchini, D
Rodrigues, D N
Riisnaes, R
Miranda, S
Figueiredo, I
Flohr, P
Nowakowska, K
de Bono, J S
Terstappen, L W M M
Attard, G
Article History
Received: 18 October 2014
Revised: 19 January 2015
Accepted: 27 January 2015
First Online: 26 February 2015
Competing interests
: The ICR developed abiraterone and therefore has a commercial interest in this agent. GA is on the ICR list of rewards to inventors for abiraterone. JSdeB has received consulting fees and travel support from Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Dendreon, Enzon, Exelixis, Genentech, GlaxoSmithKline, Medivation, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Supergen, and Takeda and grant support from AstraZeneca and Genentech. GA has received honoraria, consulting fees or travel support from Astellas, Medivation, Janssen, Millennium Pharmaceuticals, Ipsen, Takeda, and Sanofi-Aventis and grant support from Janssen and AstraZeneca. LWMMT receives grant support from Janssen Diagnostics.